Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
CardioNerds @AHA23: ORBITA-2: PCI for Stable Angina
Author(s): Rasha Al-Lamee , Christopher Rajkumar , Nazli Okumus Added: 2 years ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA… View more

Intervention
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 5 months ago

Intervention

Prevention & Chronic Conditions
The Role of Coronary Sinus Reducer Implantation for Refractory Angina
Author(s): Kevin Cheng , Jonathan M Hill , Ranil de Silva Added: 1 year ago

Intervention

Prevention & Chronic Conditions
llateral Flow Linked to Reduced Angina Pain in CAD
Added: 2 months ago Source:  Radcliffe Cardiology
A study has found that while the severity of ischaemia correlates poorly with daily angina symptoms in patients with stable coronary artery disease (CAD), the development of coronary collateral circulation is associated with both the ischaemic burden and reduced intensity of ischaemic chest pain.¹ This may help explain the often-observed disconnect between stenosis severity and patient-reported… View more

Demographic

Intervention
Added: 3 weeks ago Source:  Radcliffe Cardiology
The long-term benefits of revascularization over medical therapy for patients with stable coronary artery disease (CAD) remain a subject of clinical debate. New long-term follow-up data from the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME 2) trial provide further insight, demonstrating a sustained benefit for percutaneous coronary intervention (PCI) guided by… View more

Guidelines & Statements

Intervention
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 10 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
Invasive Strategy Linked to More Favourable Angina Trajectories in Chronic Coronary Disease
Added: 5 months ago Source:  Transcatheter Academy
While clinical trials typically report average health outcomes at specific time points, a new secondary analysis of the ISCHEMIA trial has delved into the individual patient journeys of angina symptoms over time. The study identified six distinct patterns of angina trajectories, revealing that an initial invasive strategy is associated with more favourable symptom pathways compared to a… View more

Intervention

Prevention & Chronic Conditions
Research Area(s) / Expertise:
Prof Stables is consultant cardiologist at LHCH — a specialist cardiothoracic unit and, in terms of procedure volume, one of the largest cardiac units in Europe. Prof Stables was the Chair of the Academic and Research Committee at the British Cardiovascular Society. View more
AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 2 years ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs. View more

Heart Failure

Intervention
AHA 23: 3 Trials That Will Change My Practice
Author(s): Dipti Itchhaporia Added: 2 years ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity… View more

Anticoagulation

Guidelines & Statements